Skip to main content
EyePoint Pharmaceuticals, Inc. logo

EyePoint Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · EYPT ISIN · US74440J1016 LEI · 549300QE1RU34T50MR69 US Manufacturing
Open in API
Filings indexed 1,019 across all filing types
Latest filing 2014-12-15 Director's Dealing
Country US United States of America
Listing US EYPT

About EyePoint Pharmaceuticals, Inc.

https://eyepointpharma.com/

EyePoint Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for serious retinal diseases. The company leverages its proprietary Durasert E™ technology, a bio-erodible platform for sustained intraocular drug delivery, to create durable therapies. Its lead investigational product, DURAVYU™ (EYP-1901), combines the tyrosine kinase inhibitor vorolanib with the Durasert E™ system for the potential treatment of VEGF-mediated retinal diseases. The company's goal is to improve patient outcomes and reduce treatment burden by providing long-lasting treatments for chronic eye conditions.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2014-12-15 English
FORM 10-Q
Interim / Quarterly Report Q1 2015
2014-11-07 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 7, 2014, by pSivida Corp. It announces the issuance of a press release regarding the company's first quarter fiscal year 2015 results. The document explicitly states that the press release is furnished as an exhibit and that the information is not filed for purposes of Section 18 of the Exchange Act. The content is a current report announcing earnings results but does not contain the full financial statements or detailed financial analysis itself. The document length is 2650 characters, which is relatively short and mainly serves as an announcement of the earnings release rather than the earnings release itself. According to the classification rules, initial announcements of quarterly financial results (key highlights only) are classified as Earnings Release (ER). Since this is a Form 8-K announcing the earnings release and including the press release as an exhibit, it fits best under Earnings Release (ER).
2014-11-07 English
DEF 14A
Proxy Solicitation & Information Statement
2014-10-24 English
PRE 14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A proxy statement filed with the SEC, as indicated by the header 'SCHEDULE 14A' and references to 'Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934'. It includes detailed information about the upcoming Annual Meeting of Stockholders, including date, location, agenda items such as election of directors, approval of stock option grants, ratification of stock issuances, advisory vote on executive compensation, and ratification of appointment of the independent registered public accounting firm. The document also contains voting instructions and biographies of director nominees. These characteristics align with a Proxy Solicitation & Information Statement, which is used to provide shareholders with information and request votes for meetings. The document is lengthy (15,000 characters) and contains substantive content, not just an announcement or a brief notice. Therefore, the appropriate classification is Proxy Solicitation & Information Statement (PSI).
2014-10-03 English
PRIMARY DOCUMENT
Director's Dealing
2014-10-03 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.